{"url_path":"/sec/dsgn/8-k/2026-06-11/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1807120/0001193125-26-267485-index.html","accession_number":"0001193125-26-267485","cik":"0001807120","ticker":"DSGN","issuer_name":"Design Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1807120/0001193125-26-267485-index.html","primary_entity_key":"0001807120","primary_entity_name":"Design Therapeutics, Inc."},"word_count":276,"has_tables":true,"body_markdown":"Item 5.07\n\nSubmission of Matters to a Vote of Security Holders.\n\n \n\nOn June 9, 2026, Design Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 14, 2026, the record date for the Annual Meeting, 62,441,429 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below. Voting results are, where applicable, reported by rounding fractional share voting down to the nearest whole number.\n\nProposal 1. Election of Director\n\nThe Company’s stockholders elected the one person listed below as a Class II director, to serve until the Company’s 2029 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or, if sooner, until his death, resignation or removal. The final voting results are as follows:\n\n \n\n \n\nVotes For\n\n \n\nVotes Withheld\n\n \n\nBroker Non-Votes\n\nSimeon George, M.D.\n\n \n\n29,205,208\n\n \n\n7,608,724\n\n \n\n13,264,883\n\n \n\nProposal 2. Ratification of Selection of Independent Registered Public Accounting Firm\n\nThe Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:\n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n \n\nBroker Non-Votes\n\n50,077,708\n\n \n\n201\n\n \n\n906\n\n \n\nNot applicable\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \n\nDESIGN THERAPEUTICS, INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 11, 2026\n\nBy:\n\n/s/ Pratik Shah, Ph.D.\n\n \n\n \n\n \n\nPratik Shah, Ph.D.\nPresident, Chief Executive Officer and Chairperson"}